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Abstract
Background/Objectives: Post-marketing comparative trials describe medication use patterns in 
diverse, real-world populations. Our objective was to determine if differences in rates of adherence 
and tolerability exist among new users to acetylcholinesterase inhibitors (AChEI’s).
Design: Pragmatic randomized, open label comparative trial of AChEI’s currently available in 
the United States.
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Setting: Four memory care practices within four healthcare systems in the greater Indianapolis 
area.
Participants: Eligibility criteria included older adults with a diagnosis of possible or probable 
Alzheimer’s disease (AD) who were initiating treatment with an AChEI. Participants were 
required to have a caregiver to complete assessments, access to a telephone, and be able to 
understand English. Exclusion criteria consisted of a prior severe adverse event from AChEIs.
Intervention: Participants were randomized to one of three AChEIs in a 1:1:1 ratio and followed 
for 18 weeks.
Measurements: Caregiver-reported adherence, defined as taking or not taking study medication, 
and caregiver-reported adverse events, defined as the presence of an adverse event.
Results: 196 participants were included with 74.0% female, 30.6% African Americans, and 
72.9% who completed at least 12th grade. Discontinuation rates after 18 weeks were 38.8% for 
donepezil, 53.0% for galantamine, and 58.7% for rivastigmine (p=0.063) in the intent to treat 
analysis. Adverse events and cost explained 73.1% and 25.4% of discontinuation. No participants 
discontinued donepezil due to cost. Adverse events were reported by 81.2% of all participants; no 
between-group differences in total adverse events were statistically significant.
Conclusions: This pragmatic comparative trial showed high rates of adverse events and cost-
related non-adherence with AChEIs. Interventions improving adherence and persistence to 
AChEIs may improve AD management.
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Introduction
Post-marketing clinical trials embedded within clinical environments provide valuable 
opportunities to capture natural treatment patterns within the real-world care environment. 
Comparative effectiveness research conducted in clinical practice can maximize the 
advantages of observational research through minimally intrusive data collection, and 
introduce strengths of experimental research by introducing methods such as randomization. 
Comparative effectiveness trials are an ideal way to capture treatment patterns and clinical 
outcomes among real-world populations suffering from multiple comorbidities that are often 
excluded from industry-sponsored trials.
The pro-cholinergic drugs tacrine, donepezil, galantamine and rivastigmine have been the 
standard of care for Alzheimer’s disease (AD) for more than two decades. These 
medications do not alter the natural history of the disease but they are believed to delay 
progression of cognitive and functional decline, and minimize behavioral disturbances.1, 2 In 
a Cochrane Systematic Review of 13 randomized, double blind, placebo controlled trials of 
acetylcholinesterase inhibitors (AChEI) in the treatment of dementia, one in three stopped 
treatment due to adverse effects.1
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Both cost and tolerability limit use of AChEI in older adults with dementia, however no 
randomized trial has been conducted which directly compared adherence of all three 
treatments currently available. Industry-sponsored data report discontinuation rates due to 
adverse events between 5–15%,3–5 whereas post-marketing cohort studies have reported 
discontinuation due to adverse events up to 35% as early as 12 weeks after initiation.6–8 
Existing studies were commonly conducted outside of the United States and often in 
populations with low levels of comorbidity with low rates of discontinuation due to adverse 
events,6,8 suggesting the impact of comorbid disease and multiple medications is under-
represented.9,10
Despite differences among the AChEI in pharmacologic and pharmacokinetic properties, no 
clinically-relevant differences in efficacy outcomes have been consistently reported.1, 2, 11,12 
However no randomized trial has directly compared safety and adherence in the three 
treatments available in the United States (tacrine withdrawn from the market in 2012). Our 
objective was to determine if differences in adherence and adverse events of AChEI exist in 
a real-world clinical setting among new users of AChEI.
Methods
Study Design and Setting
The study design was a pragmatic, randomized open-label clinical trial to compare 
adherence to and tolerability of the three AChEIs approved for treatment of AD. The setting 
and study methods have been previously published and are described below (http://
Clinicaltrials.gov: NCT01362686).13 Participants were enrolled from one of four healthcare 
systems within the metropolitan Indianapolis area. Each memory care practice within these 
healthcare systems provides outpatient geriatric and dementia care that includes expert 
evaluation of cognitive health, including comprehensive neuropsychologic testing, and other 
laboratory and imaging parameters recommended in the diagnosis of cognitive impairment 
and dementia. Providers in these healthcare systems include both physicians and nurse 
practitioners, and each facility has access to neuropsychologic support in the interpretation 
of neuropsychologic assessments.13 Patients, families, and primary care providers are the 
primary source of referrals. One institution also participated in a voluntary dementia 
screening study beginning in 2012 (CHOICE study: R01AG040220); otherwise no 
systematic screening approaches for dementia existed in the remaining primary care 
environments at the time of this study.
Participants
Eligible participants included those diagnosed with possible or probable AD by geriatric and 
dementia experts within memory care practices of the four healthcare systems participating 
in the study in central Indiana. Complete eligibility criteria require (1) the provider’s intent 
to initiate therapy with a AChEI; (2) consent from a legally authorized representative and 
agreement from a caregiver to complete the study outcome assessments; (3) access to a 
telephone, and (4) the ability to understand English. Patients are referred to study sites for 
cognitive or functional assessments. Although the intended target population were those 
deemed by the provider as candidates for initiation of an AChEI, prior exposure to this class 
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of medications was not a contraindication for eligibility. Those currently receiving AChEI 
therapy, or those whose prior exposure to AChEI resulted in an adverse event that prevented 
rechallenge, were excluded. Enrollment was conducted by clinical or research staff at each 
study site, and follow-up interviews were conducted by centrally located research staff.
Intervention and randomization
The study intervention is limited to the initial treatment allocation, determined by the 
randomization method described below. Beyond the initial treatment selection, the study 
followed a naturalistic, pragmatic design to accommodate the real-world clinical setting. 
Although providers were required to prescribe the AChEI generated from the randomization 
procedure, the protocol allowed providers the discretion to prescribe the dosage form and 
titrate the dose based on their clinical impression throughout the study period in 
concordance with routine clinical care. Similarly, in those who did not tolerate, could not 
afford, or did not take the assigned AChEI for any other reason, discontinuation or changes 
to another AChEI were allowed at the discretion of the provider.
The randomization process allocated participants to either donepezil (Aricept™), 
rivastigmine (Exelon™), or galantamine (Razadyne™) in a 1:1:1 ratio and was stratified by 
study site to avoid demographic or clinical differences by location. A computer-generated 
randomization scheme was implemented in REDCap, the online Research Electronic Data 
Capture web-based system for data collection available to the Clinical and Translational 
Science Institutions. Staff from each participating memory care practice had access to the 
REDCap system to follow the randomization protocol.
Regional health information exchange
Each participating study site contributes electronic medical record information to the Indiana 
Network for Patient Care (INPC). The INPC was developed in 1995 by the Regenstrief 
Institute as the first regional health information exchange. INPC has grown to integrate 
clinical information from health care systems throughout the state of Indiana and includes 
pharmacy, laboratory, encounter, diagnosis and procedural codes and a variety of other 
documentation notes and reports.14
The INPC provided diagnostic and pharmacy data to compare comorbidities within the study 
population. We used pharmacy data from the INPC to calculate a Chronic Disease Score 
(CDS).15,16 The CDS maps medication classes to chronic disease, which are then weighted 
for the risk of either mortality (CDS-Mortality) or healthcare utilization (CDS-Healthcare). 
We have previously used these measures to correlate comorbidity scores with mortality and 
healthcare utilization.17
Outcome assessment
Demographic and clinical characteristics were collected by clinic and research staff at 
baseline, and outcome assessments collected at weeks 6, 12, and 18 by telephone interviews 
with the participant’s caregiver. The first participant was enrolled on May 2, 2011, with the 
final participant enrolled on April 27th, 2014; follow-up concluded on September 15th, 2014. 
Research staff conducting follow-up interviews were initially blinded to the randomization 
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allocation, however staff did collect medication-specific adverse event information for any 
dementia medication participants were currently taking. The primary outcome was 
caregiver-reported adherence to study medication, reported as taking the randomly-allocated 
drug (Intention-to-treat analysis) or any drug in the class (per protocol analysis). If study 
medication was discontinued, the reason for discontinuation was reported as an adverse 
event, cost, forgetfulness to either fill the prescription or consume the medication as 
directed, or discontinuation by the physician for any other reason. The secondary outcome 
was caregiver-reported adverse events, defined as an adverse event thought to be due to 
study medication. Adverse events were collected through both voluntary report and as a 
forced-checklist of events. Research staff also collected care-giver reported response to 
adverse events: reported as hospital or emergency department admission, outpatient visit to 
the participant’s physician, receipt of a new medication to treat the adverse event, 
discontinuation of study medication, or other action taken as a result of the adverse event.
Power and statistical analysis
Our original sample size assumptions were based on discontinuation rates from phase III 
clinical trials and database analyses of new users of acetylcholinesterase inhibitors, and 
assumed a 15% discontinuation rate for donepezil, and 35% discontinuation rates for 
rivastigmine and galantamine within the 18 week study period.1,18 Our planned sample size 
of 300 participants would have provided 88% power to detect the difference between 
donepezil and each of the other study medications at a two-tailed significance level of 
0.05.13 A planned mid-point analysis conducted by the external data safety and monitoring 
board reviewed a blinded outcome analysis and progress on enrollment. Given a higher rate 
of discontinuation and lower rate of recruitment than anticipated, the board approved early 
termination of the study after 200 participants were enrolled.
We used Chi-square tests and Analysis of Variance (ANOVA) models to test for differences 
in demographics and comorbidities between the three randomized groups. Logistic 
regression models were used to test for differences in adherence (intention-to-treat and per 
protocol) rates between the three groups. The Holm Stepdown method of adjusting for 
multiple comparisons was used when significant differences between the three study groups 
were found.19
Ethical approval
The study was approved by the Institutional Review Board (IRB) of Indiana University 
Purdue University Indianapolis, as well as each participating healthcare system. Informed 
consent was provided by each participant’s legally authorized representative.
Results
The figure reports the flow diagram for the 196 participants who provided consent for the 
study and were included in the analysis. Demographic characteristics of the enrolled 
population are shown in table 1, with overall characteristics of 74.0% females, 30.6% 
African American, and 72.9% completing at least a high school education. The mean 
number of prescription medications captured from medical records of the INPC health 
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information exchange was 8.4 for all participants. Table 1 shows that no differences in 
demographic and clinical characteristics were identified between study groups.
Table 2 presents 18-week results of the intention-to-treat and per protocol analysis, which 
reports adherence by randomization group (intention-to-treat), and by medication consumed 
if randomized drug was not initiated (per protocol); the per protocol analysis accounts for 
participants who never consumed the medication they were randomized to receive, most 
often due to cost limitations (usually due to lack of coverage by insurance provider). 
Adherence data was obtained on 84.7% (166/196) of enrollees. There were no significant 
differences between patients who withdrew and patients who continued in the study.
Overall, 50% of the population discontinued or did not initiate the treatment they were 
randomized to receive in the intent to treat analysis. Among those who were non-adherent 
and completed at least one outcome assessment, adverse events were the most common 
reason for discontinuation of the randomized study drug (55.9%), followed by cost (29.4%). 
No caregiver reported cost as a reason for discontinuation of donepezil. The adherence rates 
did not significantly differ (p=0.063) across the three groups. Non-adherence due to cost 
differed by study group (p=0.002, intent to treat analysis); participants randomized to the 
donepezil group had significantly lower cost-related non-adherence than those randomized 
to galantamine (p=0.002) and those randomized to rivastigmine (p=0.001). There was no 
difference in cost-related non-adherence between galantamine and rivastigmine groups 
(p=0.628). The adherence rates are not significantly different (p=0.218) when examining the 
data by medication actually consumed (per protocol analysis) when excluding cost/insurance 
as a reason for non-adherence.
Table 3 reports rates of severe adverse events resulting in an acute care visit (hospital or 
emergency department), an outpatient visit, or a new medication to treat an adverse event. 
Among 121 severe adverse events, 45% occurred in conjunction with at least one other 
adverse event. The most common result of a severe adverse event was an outpatient visit 
(23% of events) and receipt of a new medication (21% of events). Thirty-one percent of 
severe adverse reactions resulted in discontinuing study medication, regardless of an 
interaction with a provider. Cumulative rates of adverse events reported by caregivers are 
presented by medication consumed in supplementary table S1. Overall, 81.2% of caregivers 
reported an adverse event due to study medication. Only nightmares were more common in 
those taking donepezil (p=0.044). Gastrointestinal, neurological, and musculoskeletal 
adverse events were the most common events for each medication.
Using the per protocol analysis, table 4 describes the proportions of study participants who 
achieved and sustained the maximum dosage of medication they received. Maximum doses 
were defined as at least 10 mg/day for donepezil, 12mg twice daily by mouth or 24mg 
extended-release once daily by mouth for galantamine, and 6mg twice daily by mouth, or at 
least the 9.5 mg patch for those receiving rivastigmine.Participants using rivastigmine were 
more likely to achieve maximum dose if using the patch dosage form compared to the oral 
form (7/20 with patch vs. 0/16 with oral form). Among participants using any form of 
galantamine, those using the XR formulation experienced a higher proportion of severe 
adverse events (71% of galantamine XR users vs. 36% of users of galantamine regular 
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release). No difference in the rate of overall adverse events (or severe adverse events) was 
identified among participants using different forms of rivastigmine. Among those not 
achieving maximum dose, 66.7% of donepezil users were adherent to a lower dose of study 
medication, 75.7% of galantamine users were adherent to a lower dose, and 62.1% of 
rivastigmine users were adherent to a lower dose.
Discussion
Results from our trial show that adverse events and cost-related non-adherence are common 
among new users of AChEI within 18 weeks of treatment initiation. We used a randomized 
study design to compare the three pharmacologic treatments, eliminating selection bias 
inherent in observational studies, and found high rates of non-adherence, but no statistically 
significant difference in adherence between treatment arms (despite a 20% absolute 
difference in adherence, donepezil vs. rivastigmine). Although overall differences in 
adherence rates were not statistically significant, cost-related non-adherence was higher for 
those randomized to galantamine and rivastigmine than those randomized to donepezil 
(p=0.002).
The primary difference in rates of adherence between groups in the intent to treat analysis 
was due to cost. This result is potentially representative of the timeframe of this study 
(enrollment occurring between 2011–2014). Cost reported as a barrier to adherence was 
primarily due to coverage from prescription payment programs and availability of generic 
products, and may not directly reflect the patient/caregiver’s willingness to pay prescription 
costs. In 2011, donepezil was the only generic medication approved in the United States and 
became the preferred medication from most third party payers when commercially available 
in early 2012. Generic forms of galantamine and rivastigmine subsequently became 
available during the study period. Among medications consumed by our study population, 
59% of donepezil users reported using only generic donepezil, 90% of galantamine users 
reported only receiving generic galantamine, and 28% of rivastigmine users reported 
receiving only generic rivastigmine. Although generic availability has increased since 
initiation of our study, some plans continue to list generic AChEI’s (particularly galantamine 
and rivastigmine) in the most costly coverage tiers. Because costs influenced adherence in 
our study, we expect poor adherence to certain AChEI’s until all generic medications are 
competitively priced.
The discontinuation rates identified in our pragmatic comparative trial are notably higher 
than those reported by industry-sponsored trials,3–5 several observational studies8, 18–24 and 
randomized trials comparing two treatments.7, 25 Not surprisingly, discontinuation rates due 
to adverse events in pre-marketing clinical trials are reported at much lower rates of 5–13% 
for mild-moderate AD.3–5 Observational studies from Italian and Spanish populations report 
variable discontinuation rates of 16.4% and 36.7%, respectively.6,12 Other studies reporting 
from administrative and claims databases have reported discontinuation rates up to 31.2% at 
6 months and 67% at 14 months.12, 21–24
Two randomized trials have compared donepezil with either rivastigmine or galantamine. 
Wilkinson and colleagues report a randomized trial comparing donepezil and rivastigmine in 
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an international sample of older adults with mild-moderate AD, with discontinuation rates 
due to adverse events of 10.7% for the donepezil and 21.8% for the rivastigmine groups.7 A 
second study comparing galantamine and donepezil in 188 older adults in the United 
Kingdom found discontinuation rates due to adverse events of 13.4% (galantamine) and 
13.2% (donepezil).25 Differences between our results and prior randomized trials likely 
reflect the degree of comorbidity and use of concomitant medications between populations 
included in international studies compared to our mid-west American sample.
We also identified notable differences in rates and distribution of adverse events in our real-
world populations compared with those reported in industry-sponsored trials. Interestingly, 
the rate of adverse events reported in our study occurred despite few participants achieving 
recommended doses. Gastrointestinal adverse events in industry-sponsored trials report rates 
from 19% in donepezil trials3 to 47% in rivastigmine trials.4 Gastrointestinal adverse events, 
as a group, were reported at a rate of approximately 50% by our population. Notably, central 
nervous system and musculoskeletal system adverse events were reported by approximately 
50% of our study population as well, whereas rates reported in industry-sponsored trials 
were much lower at approximately 20% and 10%.3–5 Improving tolerability and persistence 
to AChEIs may improve long-term treatment outcomes and reduce psychotropic use in 
patients with AD.8
Although this study is the first pragmatic randomized trial of all three AChEIs and has 
several strengths, some limitations are worth noting. First, with 166 participants included in 
the analysis, we had 20.8% power to determine the observed effect size between donepezil 
and galantamine, and 52.2% power to detect the observed difference between donepezil and 
rivastigmine, thereby introducing the potential for type II error. Second, participant selection 
is expected to be consistent with the FDA-approved use of the study medications, which 
includes a diagnosis of probable or possible AD. Such diagnoses may vary by practitioner 
and result in a heterogeneous mixture of participants with AD with or without mixed 
pathologies. However, because the intent was to study adherence and tolerability and not 
efficacy, we expect the impact on generalizability to be minimal. Third, caregiver-reported 
outcomes may differ from participant-reported outcomes and may complicate the 
comparison of results to other studies. Additionally, outcome assessors were not blinded to 
treatment, introducing the potential for measurement bias. Fourth, adverse events were 
reported through both voluntary and prompted methods, which may have overestimated the 
prevalence. Adverse events were also reported irrespective of dose; faster titration schedules 
and higher doses are known to provoke a higher rate of adverse events. However, few 
participants in our study achieved maximum recommended doses. Lastly, given the 18-week 
duration of the study, the use of caregiver-reported adherence as our primary outcome may 
better reflect a measure of early persistence rather than adherence over time.
Findings from this pragmatic comparative trial support tolerability and cost as common 
reasons reported for discontinuation of AChEI, partially explaining poor penetration of these 
medications in clinical care.26 This under-treatment phenomenon may result in un-realized 
therapeutic benefit for the growing population with AD.8 Methods to identify and reduce 
adverse events may result in a larger proportion of patients benefiting from longer periods of 
treatment. Similarly, competitive pricing of available generics can minimize cost-related 
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non-adherence between medications in the class. Given that no disease-modifying therapies 
are currently available, increasing the use of currently-available treatments may reduce the 
symptom burden and lower costs required to care for the population with AD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure: 
Description of participant flow through study procedures.
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Table 1.
Demographic and clinical characteristics of study participants
Overall (n = 196) Donepezil (n=67) Galantamine (n=66) Rivastigmine (n=63) P-value
Age, mean (SD) 80.2 (8.4) 79.1 (7.6) 80.1 (9.6) 81.6 (7.8) 0.264
Gender 0.300
 Male, n (%) 51 (26.0%) 19 (28.4%) 20 (30.3%) 12 (19.0%)
 Female, n (%) 145 (74.0%) 48 (71.6%) 46 (69.7%) 51 (81.0%)
Ethnicity 0.641
 Hispanic, n (%) 5 (2.6%) 1 (1.5%) 2 (3.0%) 2 (3.2%)
 Not Hispanic, n (%) 188 (95.9%) 66 (98.5%) 62 (93.9%) 60 (95.2%)
 Unknown, n (%) 3 (1.5%) 0 (0.0%) 2 (3.0%) 1 (1.6%)
Race 0.204
 Other, n (%) 2 (1.0%) 0 (0.0%) 1 (1.5%) 1 (1.6%)
 African American, n (%) 60 (30.6%) 26 (38.8%) 21 (31.8%) 13 (20.6%)
 White, n (%) 134 (68.4%) 41 (61.2%) 44 (66.7%) 49 (77.8%)
Education 0.619
 Less than HS, n (%) 17 (8.8%) 4 (6.0%) 8 (12.5%) 5 (7.9%)
 Some HS, n (%) 34 (17.5%) 14 (20.9%) 7 (10.9%) 13 (20.6%)
 HS Graduate, n (%) 67 (34.5%) 23 (34.3%) 21 (32.8%) 23 (36.5%)
 Some College, n (%) 76 (39.2%) 26 (38.8%) 28 (43.8%) 22 (34.9%)
Caregiver Relationship to Patient 0.615
 Spouse, n (%) 40 (25.0%) 15 (26.8%) 12 (22.6%) 13 (25.5%)
 Daughter, n (%) 75 (46.9%) 26 (46.4%) 24 (45.3%) 25 (49.0%)
 Son, n (%) 24 (15.0%) 5 (8.9%) 10 (18.9%) 9 (17.6%)
 Other, n (%) 21 (13.1%) 10 (17.9%) 7 (13.2%) 4 (7.8%)
Comorbidities
 Vascular Disease, n (%) 35 (25.7%) 13 (25.5%) 13 (27.1%) 9 (24.3%) 0.958
 COPD, n (%) 36 (26.5%) 14 (27.4%) 11 (22.9%) 11 (29.7%) 0.764
 Hypertension, n (%) 77 (56.6%) 33 (64.7%) 24 (50.0%) 20 (54.0%) 0.315
 CHF, n (%) 67 (49.3%) 25 (49.0%) 25 (52.1%) 17 (46.0%) 0.854
 Affect Disorder, n (%) 64 (47.1%) 23 (45.1%) 21 (43.8%) 20 (54.0%) 0.602
 Diabetes, n (%) 25 (18.4%) 10 (19.6%) 12 (25.0%) 3 (8.1%) 0.132
 Hyperlipidemia, n (%) 81 (59.6%) 28 (54.9%) 32 (66.7%) 21 (56.8%) 0.452
 Diuretic, n (%) 47 (34.6%) 16 (31.4%) 15 (31.2%) 16 (43.2%) 0.428
CDS Score – Health Care* 0.798
 Mean (SD) 7.6 (4.5) 7.3 (4.5) 7.8 (4.8) 7.8 (4.0)
CDS Score – Mortality * 0.840
 Mean (SD) 5.7 (3.5) 5.4 (3.5) 5.9 (3.9) 5.8 (2.9)
Dispensed Prescription Medications 0.818
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Overall (n = 196) Donepezil (n=67) Galantamine (n=66) Rivastigmine (n=63) P-value
 Mean (SD) 8.1 (4.7) 8.0 (5.1) 7.9 (4.4) 8.6 (4.7)
*CDS: Chronic Disease Score derived from dispensed pharmacy data 12 months prior to enrollment
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Table 2.
Adherence rates by both intention-to-treat and per protocol analysis.
Intention to Treat
Donepezil (n=67) Galantamine (n=66) Rivastigmine (n=63) p-value
Non-adherent, n (%)* 26 (38.8%) 35 (53.0%) 37 (58.7%) 0.063
Reasons for non-adherence:
Withdrew/lost to follow-up (no outcome assessment) 8 (11.9%) 12 (18.2%) 10 (15.9%) 0.599
 Cost, n (%) 0 (0.0%) 9 (13.6%) 11 (17.5%) 0.002
 Adverse drug event, n (%) 13 (19.4%) 12 (18.2%) 13 (20.6%) 0.974
 Forgot, Lost, Never started, n (%) 4 (6.0%) 1 (1.5%) 2 (3.2%) 0.406
 Unknown 1 (1.5%) 1 (1.5%) 1 (1.6%) 1.000
Per Protocol#
Donepezil (n=79) Galantamine (n=46) Rivastigmine (n=41) p-value
Non-adherent, n (%)* 19 (24.1%) 15 (32.6%) 16 (39.0%) 0.218
Reasons for non-adherence:
 Cost, n (%) 0 (0.0%) 1 (2.2%) 0 (0.0%) 0.524
 Adverse drug event, n (%) 14 (17.7%) 12 (26.1%) 13 (34.1%) 0.193
 Forgot, Lost, Never started, n (%) 4 (5.1%) 1 (2.2%) 2 (4.9%) 0.784
 Unknown 1 (1.3%) 1 (2.2%) 1 (2.4%) 1.000
*Adherence defined as caregiver-report of continued medication use. P-value for difference between groups is 0.063 for Intent-to-treat analysis, and 
0.218 for per-protocol analysis.
#
The per protocol analysis reports study groups by the medication received, and excluded those who withdrew and/or did not complete an outcome 
assessment.
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Table 3:
Proportion of study participants experiencing severe adverse events
Donepezil (n=79) Galantamine (n=46) Rivastigmine (n=41)
Cardiovascular - total 8.8% 6.5% 12.2%
 Fast or slowed heart rate 7.6% 0.0% 7.3%
 Irregular heartbeat (arrhythmia) 6.3% 6.5% 4.9%
Neuro – all other 31.7% 23.9% 26.8%
 Fainting 2.5% 2.2% 4.9%
 Dizziness 6.3% 13.0% 17.1%
 Nightmares 8.9% 4.4% 2.4%
 Headache 10.1% 4.4% 7.3%
 Seizures or fits 1.3% 2.2% 0.0%
 Sleeplessness or poor sleep (insomnia) 12.7% 4.4% 14.6%
Gastrointestinal – total 26.6% 19.6% 29.3%
 Upset stomach 15.2% 6.5% 19.5%
 Vomiting 5.1% 6.5% 7.3%
 Diarrhea 16.5% 10.9% 17.1%
 Lack of interest in eating (anorexia) 12.7% 4.4% 9.8%
Musculoskeletal – total 25.3% 21.7% 26.8%
 Muscle cramps 8.9% 10.9% 4.9%
 Pain 6.3% 13.0% 7.3%
 Falls 0.0% 0.0% 7.3%
 Feeling tired (Fatigue) 11.4% 6.5% 7.3%
 Tremor or shaking 7.6% 2.2% 7.3%
Incontinence – total 11.4% 8.7% 7.3%
 Incontinence of urine or stool
Respiratory – total 3.8% 8.7% 4.9%
 Asthma/wheezing or trouble breathing
Entorhinal – total 16.5% 4.4% 4.9%
 Runny nose (rhinitis)
Interaction may have included any or more than one of the following: acute care visit (hospital or emergency department), outpatient visit, or 
receipt of a new medication to treat an adverse event.
p-value for difference between groups: entorhinal total = 0.048
p-value for difference between groups: falls = 0.014
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Table 4:
Proportion of study participants in Per Protocol analysis achieving and maintaining maximum dose of 
acetylcholinesterase inhibitors.
% Achieving Max Dose % Achieving Max Dose on last interview
Donepezil (n=76) 52.6% 42.9%
Galantamine *(n=39) 5.1% 2.6%
Rivastigmine^(n=36) 19.4% 16.7%
*Once-daily dosage form prescribed to 35.9% of participants taking galantamine
^
Patch dosage form prescribed to 55.6% of participants taking rivastigmine
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